Supplementary data

Supplementary Table 1. Yearly dual antiplatelet therapy prescription rate in the MAGSTEMI trial according to allocation.

	MgBRS (n=74)	SES (n=76)	Difference (95% CI)	p-value
1-year	4 (5.4%	2 (2.6%)	-2.8 (-9.1 to 3.5)	0.386
2-year	6 (8.1%)	2 (2.6%)	5.5 (-12.7 to 1.7)	0.136
3-year	7 (9.5)	3 (3.9)	-5.5 (-13.5 to 2.5)	0.176

95% CI: 95% confidence interval; MgBRS: magnesium-based bioresorbable scaffold; SES: permanent metallic sirolimus-eluting stent

Supplementary Table 2. Bleeding events at 3-year follow-up according to allocated device and antiplatelet therapy at the moment of the event.

Patient	Device	Time to event (months)	Antiplatelet therapy at the moment of the event
1	MgBRS	1.0	Aspirin+clopidogrel
2	MgBRS	3.2	Aspirin
3	MgBRS	3.3	Aspirin+clopidogrel
4	SES	4.5	Aspirin
5	MgBRS	5.9	Aspirin+ticagrelor
6	SES	10.6	Aspirin+prasugrel
7	MgBRS	18.3	Aspirin
8	MgBRS	20.2	Aspirin
9	SES	25.6	Aspirin+ticagrelor
10	MgBRS	27.7	Aspirin

MgBRS: magnesium-based bioresorbable scaffold; SES: permanent metallic sirolimus-eluting stent



Supplementary Figure 1. Yearly dual antiplatelet therapy prescription in the MAGSTEMI trial according to its relationship with adverse events and allocation.

DAPT: dual antiplatelet therapy; MgBRS: magnesium-based bioresorbable scaffold; SES: permanent metallic sirolimus-eluting stent